Granted Patent
B2
US 12,668,590 · App. 18/199,827 · Granted Jun 30, 2026
Composition and method for treating metabolic disorders
Assignee:
VeroScience LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.
Claims (14)
1 . The method of treating obesity which comprises administering to a subject in need of such treatment a pharmaceutical composition comprising an effective amount for treating the obesity of bromocriptine citrate.
2 . The method of claim 1 wherein the effective amount is between 0.05 μg and 0.5 mg/kg of body weight per day.
3 . The method of claim 1 which comprises administering the pharmaceutical composition at a time of day that will increase central dopaminergic activity of the subject at the time of day of the circadian peak of central dopaminergic activity in a healthy individual of the same species and sex.
4 . The method of claim 3 which comprises administering the pharmaceutical composition between 0400 and 1200 hours of the day.
5 . The method of claim 1 wherein the pharmaceutical composition comprises a tablet.
6 . The method of claim 5 wherein the tablet comprises a sublingual tablet.
7 . The method of claim 1 which comprises administering the pharmaceutical composition via the sublingual route.
8 . The method of claim 3 which comprises administering the pharmaceutical composition within two hours after awakening.
9 . The method of claim 3 which comprises administering the pharmaceutical composition between 4 hours before and four hours after the onset of daily locomotor activity.
10 . The method of claim 3 which comprises administering the pharmaceutical composition between two hours before and two hours after the onset of daily locomotor activity.
11 . The method of claim 1 which comprises administering the pharmaceutical composition in an oral dosage form.
12 . The method of claim 1 which comprises parenterally administering the bromocriptine citrate.
13 . The method of claim 1 which comprises co-administering at least one of an alpha-I adrenergic antagonist, an alpha 2 adrenergic agonist, a serotonergic inhibitor or a serotonin 5HT1b agonist with the bromocriptine citrate.
14 . The method of claim 1 which comprises administering the pharmaceutical composition via the sublingual route.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 19, 2023
From: CINCOTTA, ANTHONY H., PHD
To: VEROSCIENCE LLC
Reel/Frame 063709/0657 →
Continuity (6)
Provisional Application
62325342
· Apr 20, 2016
References Cited (251)
US 941005A
· Brandt
· 1909
[cited by applicant]
US 3752814A
· Fluckiger
· 1973
[cited by applicant]
US 4654345A
· Cavanak
· 1987
[cited by applicant]
US 4659715A
· Meier et al.
· 1987
[cited by applicant]
US 4749709A
· Meier et al.
· 1988
[cited by applicant]
US 4783469A
· Meier et al.
· 1988
[cited by applicant]
US 4962197A
· Foley et al.
· 1990
[cited by applicant]
US 5006526A
· Meier et al.
· 1991
[cited by applicant]
US 5066495A
· Moro et al.
· 1991
[cited by applicant]
US 5186420A
· Beauchamp et al.
· 1993
[cited by applicant]
US 5344832A
· Cincotta et al.
· 1994
[cited by applicant]
US 5468755A
· Cincotta et al.
· 1995
[cited by applicant]
US 5496803A
· Meier et al.
· 1996
[cited by applicant]
US 5523082A
· Corbiere
· 1996
[cited by applicant]
US 5554623A
· Cincotta et al.
· 1996
[cited by applicant]
US 5565454A
· Cincotta
· 1996
[cited by applicant]
US 5585347A
· Meier et al.
· 1996
[cited by applicant]
US 5626860A
· Cincotta et al.
· 1997
[cited by applicant]
US 5635512A
· Cincotta et al.
· 1997
[cited by applicant]
US 5654313A
· Cincotta et al.
· 1997
[cited by applicant]
US 5668155A
· Cincotta et al.
· 1997
[cited by applicant]
US 5679685A
· Cincotta et al.
· 1997
[cited by applicant]
US 5688794A
· Meier et al.
· 1997
[cited by applicant]
US 5696128A
· Meier et al.
· 1997
[cited by applicant]
US 5700795A
· Meier et al.
· 1997
[cited by applicant]
US 5700800A
· Cincotta et al.
· 1997
[cited by applicant]
US 5712265A
· Meier et al.
· 1998
[cited by applicant]
US 5714519A
· Cincotta et al.
· 1998
[cited by applicant]
US 5716932A
· Meier et al.
· 1998
[cited by applicant]
US 5716933A
· Meier et al.
· 1998
[cited by applicant]
US 5716957A
· Cincotta et al.
· 1998
[cited by applicant]
US 5716962A
· Cincotta et al.
· 1998
[cited by applicant]
US 5719160A
· Cincotta et al.
· 1998
[cited by applicant]
US 5731287A
· Meier et al.
· 1998
[cited by applicant]
US 5731312A
· Cincotta et al.
· 1998
[cited by applicant]
US 5741503A
· Cincotta et al.
· 1998
[cited by applicant]
US 5744477A
· Meier et al.
· 1998
[cited by applicant]
US 5750519A
· Cincotta et al.
· 1998
[cited by applicant]
US 5756513A
· Meier et al.
· 1998
[cited by applicant]
US 5760047A
· Meier et al.
· 1998
[cited by applicant]
US 5792748A
· Meier et al.
· 1998
[cited by applicant]
US 5814638A
· Lee et al.
· 1998
[cited by applicant]
US 5830895A
· Cincotta et al.
· 1998
[cited by applicant]
US 5854255A
· Cincotta et al.
· 1998
[cited by applicant]
US 5866584A
· Cincotta et al.
· 1999
[cited by applicant]
US 5872127A
· Meier et al.
· 1999
[cited by applicant]
US 5872133A
· Meier et al.
· 1999
[cited by applicant]
US 5877183A
· Cincotta
· 1999
[cited by applicant]
US 5902811A
· Cincotta
· 1999
[cited by applicant]
US 5905083A
· Meier et al.
· 1999
[cited by applicant]
US 5952329A
· Cincotta et al.
· 1999
[cited by applicant]
US 6004972A
· Meier et al.
· 1999
[cited by applicant]
US 6071914A
· Meier et al.
· 2000
[cited by applicant]
US 6075020A
· Meier et al.
· 2000
[cited by applicant]
US 6855707B2
· Cincotta
· 2005
[cited by applicant]
US 7888310B2
· Cincotta
· 2011
[cited by applicant]
US 8021681B2
· Cincotta
· 2011
[cited by applicant]
US 8137992B2
· Cincotta
· 2012
[cited by applicant]
US 8137993B2
· Cincotta
· 2012
[cited by applicant]
US 8137994B2
· Cincotta
· 2012
[cited by applicant]
US 8431155B1
· Cincotta et al.
· 2013
[cited by applicant]
US 8613947B2
· Cincota et al.
· 2013
[cited by applicant]
US 8741918B2
· Cincotta
· 2014
[cited by applicant]
US 8821915B2
· Cincotta
· 2014
[cited by applicant]
US 8877708B2
· Cincotta
· 2014
[cited by applicant]
US 9192576B2
· Cincotta et al.
· 2015
[cited by applicant]
US 9205084B2
· Cincotta
· 2015
[cited by applicant]
US 9352025B2
· Cincotta
· 2016
[cited by applicant]
US 9364515B2
· Cincotta
· 2016
[cited by applicant]
US 9415005B2
· Cincotta
· 2016
[cited by applicant]
US 9522117B2
· Cincotta et al.
· 2016
[cited by applicant]
US 9655865B2
· Cincotta
· 2017
[cited by applicant]
US 9700555B2
· Cincotta et al.
· 2017
[cited by applicant]
US 9895422B2
· Cincotta
· 2018
[cited by applicant]
US 9925186B2
· Cincotta
· 2018
[cited by applicant]
US 9993474B2
· Cincotta et al.
· 2018
[cited by applicant]
US 9999653B2
· Cincotta
· 2018
[cited by applicant]
US 20010016582A1
· Cincotta
· 2001
[cited by applicant]
US 20010049350A1
· Cincotta et al.
· 2001
[cited by applicant]
US 20020146400A1
· Cincotta
· 2002
[cited by applicant]
US 20040028613A1
· Quay
· 2004
[cited by applicant]
US 20040077679A1
· Cincotta
· 2004
[cited by applicant]
US 20040081678A1
· Cincotta
· 2004
[cited by applicant]
US 20040102383A1
· Cincotta et al.
· 2004
[cited by applicant]
US 20040220190A1
· Cincotta
· 2004
[cited by applicant]
US 20050054652A1
· Cincotta
· 2005
[cited by applicant]
US 20050054734A1
· Cincotta
· 2005
[cited by applicant]
US 20050215558A1
· Cincotta
· 2005
[cited by applicant]
US 20060258589A1
· McTavish
· 2006
[cited by applicant]
US 20080200453A1
· Cincotta
· 2008
[cited by applicant]
US 20090110674A1
· Loizou
· 2009
[cited by applicant]
US 20090137598A1
· Cincotta
· 2009
[cited by applicant]
US 20100035886A1
· Nivorozhkin et al.
· 2010
[cited by applicant]
US 20130274246A1
· Cincotta
· 2013
[cited by applicant]
US 20140051685A1
· Cincotta
· 2014
[cited by applicant]
US 20140275235A1
· Deleyrolle et al.
· 2014
[cited by applicant]
US 20150011554A1
· Cincotta et al.
· 2015
[cited by applicant]
US 20170209539A1
· Cincotta
· 2017
[cited by applicant]
US 20170305898A1
· Cincotta
· 2017
[cited by applicant]
US 20170340271A1
· Cincotta
· 2017
[cited by applicant]
US 20180177874A1
· Cincotta
· 2018
[cited by applicant]
US 20190160059A1
· Cincotta et al.
· 2019
[cited by applicant]
US 20210401824A1
· Cincotta
· 2021
[cited by applicant]
US 20220125379A1
· Cincotta
· 2022
[cited by applicant]
US 20220142960A1
· Cincotta et al.
· 2022
[cited by applicant]
US 20250375406A1
· Cincotta
· 2025
[cited by applicant]
US 20260062409A1
· Cincotta
· 2026
[cited by applicant]
CA 2166204
· 2009
[cited by applicant]
CN 102283844
· 2014
[cited by applicant]
CN 102727894
· 2015
[cited by applicant]
GB 2192541
· 1988
[cited by applicant]
JP H02121919
· 1990
[cited by applicant]
JP 2021500357
· 2021
[cited by applicant]
WO WO2002083141
· 2002
[cited by applicant]
WO WO2009091576
· 2009
[cited by applicant]
WO WO2013165902
· 2013
[cited by applicant]
WO WO2017184875
· 2017
[cited by applicant]
WO WO2019079623A1
· 2019
[cited by applicant]
WO WO2020011854A1
· 2020
[cited by applicant]
Holt et al., Diabetes, Obesity and Metabolism 12: 1048-1057, 2010 (Year: 2010).
[cited by examiner]
Cinocotta et al., Life Sciences, vol. 61, No. 10, pp. 951-956, 1997 (Year: 1997).
[cited by examiner]
Granchi et al., “Anti-cancer agents counteracting tumor glycolysis,” ChemMedChem, Aug. 2012, 7(8):1318-1350.
[cited by applicant]
Office Action in European Appln No. 21189773.1, mailed on Sep. 16, 2024, 5 pages.
[cited by applicant]
Sun et al., “Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumors,” Photochem. Photobiol. Science, Jul. 16, 2002, 1:690-695.
[cited by applicant]
[No Author Listed], “Dissolution,” General Chapter 711, U.S. Pharmacopoeia (USP), 34th ed., Dec. 1, 2011, 8 pages.
[cited by applicant]
Alkarakooly et al., “Metabolic reprogramming by Dichloroacetic acid potentiates photodynamic therapy of human breast adenocarcinoma MCF-7 cells,” PLOS One, Oct. 23, 2018, 13(10):e0206182.
[cited by applicant]
Ashton et al., “Oxidative Phosphorylation as an Emerging Target in Cancer Therapy,” Clinical Cancer Research, 2018, 24(11):2482-2490.
[cited by applicant]
Berge et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences, 1977, 66(1):1-19.
[cited by applicant]
Cincotta et al., “Novel benzophenothiazinium photosensitizers: preliminary in-vivo results,” Photodynamic Therapy: Mechanisms II, SPIE, 1990, 1203:202-210.
[cited by applicant]
Cincotta et al., “Novel Phenothiazinium Photosensitizers for Photodynamic Therapy,” SPIE Proceedings, Advances in Photochemotherapy, 1988, 997:145-153.
[cited by applicant]
Cincotta et al., “Novel Photodynamic Effects of a Benzophenothiazine on Two Different Murine Sarcomas,” Cancer Research, Mar. 1, 1994, 54:1249-1258.
[cited by applicant]
Cincotta et al., “Novel red absorbing benozoaphenoxazinium and benzoaphenothiazinium photosensitizers: in vitro evaluation,” PhotoChemistry and PhotoBiology, Nov. 1987, 46(5):751-758.
[cited by applicant]
Cincotta et al., “Phototoxicity, Redox Behavior, and Pharmacokinetics of Benzophenoxazine Analogues in EMT-6 Murine Sarcoma Cells,” Cancer Research, Jun. 1, 1993, 53:2571-2580.
[cited by applicant]
Deni et al., “Glucose-functionalized amino-OPEs as biocompatible photosensitizers in PDT,” European Journal of Medicinal Chemistry, Jan. 28, 2016, 11:58-71.
[cited by applicant]
Detty et al., “Current clinical and preclinical photosensitizers for use in photodynamic therapy,” Journal of Medicinal Chemistry, 2004, 47(16):3897-3915.
[cited by applicant]
Dietrich et al., “Non-alcoholic fatty liver disease, obesity and the metabolic syndrome,” Best Practice & Research Clinical Gastroenterology, 2014, 28:637-653.
[cited by applicant]
EP Extended European Search Report in European Appln No. 18868516.8, dated Jun. 29, 2021, 8 pages.
[cited by applicant]
Fadlan et al., “Synthesis, photophysical properties, and photodynamic activity of positional isomers of TFPP-glucose conjugates,” Bioorganic & Medicinal Chemistry, Feb. 19, 2018, 26(8):1848-1858.
[cited by applicant]
Fadok et al., “Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: roles of proteases,” Journal of Immunology, 2001, 166:6847-6854.
[cited by applicant]
Fan et al., “Hyperglycemia enhances the effectiveness of PDT,” Proceedings of SPIE, 1995, 2392:36-39.
[cited by applicant]
Feng et al., “Energy metabolism targeted drugs synergize with photodynamic therapy to potentiate breast cancer cell death,” Photochemical & Photobiological Science, Oct. 9, 2014, 13:1792-1803.
[cited by applicant]
Foley et al., “Structure and Properties of Novel BenzoαPhenoxazinium Photochemotherapeutic Agents,” SPIE Proceedings, New Directions in Photodynamic Therapy, 1987, 847:90-95.
[cited by applicant]
Foultier et al., “Photosensitization of L12 10 leukemic cells by argon laser irradiation after incubation with haematoporphyrin derivative and rhodamine 123,” J Photochem. Photobiol. B: Biol. 1991, 10:119-132.
[cited by applicant]
Frimberger et al., “Photodynamic Therapy of Naturally Occurring Tumors in Animals Using a Novel Benzophenothiazine Photosensitizer,” Clinical Cancer Research, 1998, 4:2207-2218.
[cited by applicant]
Gould, “Salt selection for basic drugs,” International Journal of Pharmaceutics, 1986, 33:201-217.
[cited by applicant]
Granchi et al., “Anti-cancer agents counteracting tumor glycolsis,” ChemMedChem, Aug. 2012, 7(8):1318-1350.
[cited by applicant]
Hayashi et al., “A Novel Photodynamic Therapy Targeting Cancer Cells and Tumor-Associated Macrophages,” Molecular Cancer Therapeutics, 2015, 14(2):452-460.
[cited by applicant]
Hendrzak-Henion et al., “Role of the immune system in mediating the antitumor effect of benzophenothiazine photodynamic therapy,” Photochemistry and Photobiology, 1999, 69(5):575-581.
[cited by applicant]
Lin et al., “Lysosomal Localization and Mechanism of Uptake of Nile Blue Photosensitizers in Tumor Cells,” Cancer Research, 1991, 51:2710-2719.
[cited by applicant]
Lin et al., “Photosensitization, Uptake, and Retention of Phenoxazine Nile Blue Derivatives in Human Bladder Carcinoma Cells,” Cancer Research, 1991, 51:1109-1116.
[cited by applicant]
Liu et al., “EtNBSe-PDT inhibited proliferation and induced autophagy of HNE-1 cells via downregulating the Wnt/beta-catenin signaling pathway,” Photodiagnosis and Photodynamic Therapy, Mar. 1, 2019, 26:65-72.
[cited by applicant]
Martin et al., “A concomitant ATP-depleting strategy markedly enhances anticancer agent activity,” Apoptosis, 2001, 6(1/2):125-131.
[cited by applicant]
Nelson et al., “Glucose administration combined with photodynamic therapy of cancer improves therapeutic efficacy,” Lasers in Surgery and Medicine, 1992, 12:153-158.
[cited by applicant]
Nishie et al., “Excellent antitumor effects for gastrointestinal cancers using photodynamic therapy with a novel glucose conjugated chlorin e6, Biochemical and Biophysical Research Communications,” Jan. 2018, 496(4):120…
[cited by applicant]
Oberdanner et al., “Glucose is Required to Maintain High ATP-levels for the Energy-utilizing Steps During PDT-induced Apoptosis,” Photochemistry and Photobiology, 2002, 76(6):695-703.
[cited by applicant]
Osinsky et al., “Tumour pH under induced hyperglycemia and efficacy of chemotherapy,” Anticancer Research, 1987, 7(2):199-201.
[cited by applicant]
Pan, “Industrial Pharmaceutics,” China Medical Science and Technology Press, the first printing of the 3rd edition, Aug. 2015, p. 47 (Partial English Translation only).
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2017/028656, mailed on Oct. 23, 2018, 6 pages.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln PCT/US2018/056554, dated Apr. 21, 2020, 15 pages.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2020/052278, dated Mar. 15, 2022, 7 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in Application No. PCT/US2017/028656, mailed on Jul. 7, 2017, 13 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appl. PCT/US2018/056554, dated, Jan. 3, 2019, 17 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2020/052278, dated Feb. 10, 2021, 9 pages.
[cited by applicant]
Pelicano et al., “Glycolysis inhibition for anticancer treatment,” Oncogene, 2006, 25:4633-4646.
[cited by applicant]
Pukngam et al., “Development and Validation of a Stability-Indicating HPLC Method for Determination of Bromocriptine Mesylate in Bulk Drug and Tablets,” Current Pharmaceutical Analysis, 2013, 9:92-101.
[cited by applicant]
Ramu et al., “Glucose-appended platinum(II)-BODIPY conjugates for targeted photodynamic therapy in red light,” Inorganic Chemistry, Feb. 5, 2018, 57(4):1717-1726.
[cited by applicant]
Rathbone et al., academia.edu [Online], “Modified-Release Drug Delivery Technology,” Marcel Dekker, Inc., 2003, [Retrieved on Nov. 23, 2018], retrieved from: URL<https:www.academia.edu/28583222/Modified-Release_Drug_Del…
[cited by applicant]
Reiter et al., “Cutting edge: differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activities,” Journal of Immunology, 1999, 163:1730-1732.
[cited by applicant]
Rowe et al., “Mannitol,” Handbook of Pharmaceutical Excipients, 7th ed., 2012, 479-482.
[cited by applicant]
Rowe et al., “Stearic Acid,” Handbook of Pharmaceutical Excipients, 6th ed, 2009, 697-699.
[cited by applicant]
Sauter et al., “Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells,” Journal of Experimental Medici…
[cited by applicant]
Singh et al., “Dosage Forms: Non-Parenteral, ” Encyclopedia of Pharmaceutical Technology, 2008, 749-761.
[cited by applicant]
Stahl et al., “Pharmaceutical Salts: Properties, Selection, and Use,” Wiley-VCH, IUPAC, 2002, 329-345.
[cited by applicant]
Sun et al., “Neutrphils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumors,” Photochem. Photobiol. Science, Jul. 16, 2002, 1:690-695.
[cited by applicant]
Uruma et al., “Synthesis and biological evaluation of glucose conjugated phthalocyanine as a second-generation photosensitizer,” Bioorganic & Medicinal Chemistry, Jun. 4, 2019, 27:3279-3284.
[cited by applicant]
Vicchi et al., “Dopaminergic drugs in type 2 diabetes and glucose homeostasis,” Pharmacological Research, 2016, 109:74-80.
[cited by applicant]
Office Action in Japanese Appln. No. 2023-018110, mailed on Apr. 2, 2024, 5 pages (with English translation).
[cited by applicant]
Office Action (Decision of Reexamination) in Chinese Appln. No. 201780038243.6, mailed on Feb. 25, 2025, 32 pages (with Machine Translation).
[cited by applicant]
Dolmans et al., “Photodynamic therapy for cancer,” Nat Rev Cancer, May 2003, 3(5):380-387.
[cited by applicant]
Giron-Forest et al., “Bromocriptine Methanesulphonate”, Analytical Profiles of Drug Substances, 1979, vol. 8, pp. 47-81 (Abstract Only).
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2023/026236, mailed on Jan. 2, 2025, 11 pages.
[cited by applicant]
International Search Report in International Appln. No. PCT/US2023/026236, mailed on Jan. 10, 2024, 15 pages.
[cited by applicant]
Invitation to Pay Additional Fees and, Where Applicable, Protest Fee in International Appln. No. PCT/US2023/026236, mailed on Sep. 28, 2023, 2 pages.
[cited by applicant]
Office Action (Notification of Reexamination) in Chinese Appln. No. 201780038243.6, mailed on Jan. 14, 2025, 22 pages (with English translation).
[cited by applicant]
Anderson et al., “Preparation of water-soluble organic compounds by salt formation,” The Practice of Medicinal Chemistry, Technomics Inc, vol. 2, Chapter 34, pp. 347-365.
[cited by applicant]
Office Action in Japanese Appln. No. 2024190314, mailed on Jan. 20, 2026, 11 pages (with English translation).
[cited by applicant]